Neoplasms Clinical Trials in Nashville, Tennessee

8 studies are recruiting for neoplasms in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o…

   Stage

   Phase 2

   Ages

   Any age

   Site

   Sarah Cannon Research Inst, Nashville, Tennessee

   Locations

   222 in total

   Run by

   Celgene

   See if you can join NCT03435796 on ClinicalTrials.gov

2. A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

   Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential c…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Nashville, Tennessee

   Locations

   27 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT07213609 on ClinicalTrials.gov

3. A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

   The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Cancer Institute, Nashville, Tennessee

   Locations

   41 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06150157 on ClinicalTrials.gov

4. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

   This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was design…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   86 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT05386108 on ClinicalTrials.gov

5. A Study of JNJ-87890387 for Advanced Solid Tumors

   The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   6 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06178614 on ClinicalTrials.gov

6. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

   This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville, Tennessee

   Locations

   19 in total

   Run by

   Marengo Therapeutics, Inc.

   See if you can join NCT05592626 on ClinicalTrials.gov

7. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

   The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Nashville, Tennessee

   Locations

   65 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06431594 on ClinicalTrials.gov

8. A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

   The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combinat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Nashville, Tennessee

   Locations

   67 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06551142 on ClinicalTrials.gov